A novel mutation (Leu60Pro) in a Chinese pedigree with hereditary factor XI deficiency.


Journal

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551

Informations de publication

Date de publication:
01 Sep 2021
Historique:
pubmed: 15 1 2021
medline: 27 11 2021
entrez: 14 1 2021
Statut: ppublish

Résumé

To analyse F11 gene mutations in a Chinese pedigree with hereditary factor XI (FXI) deficiency and investigate the molecular mechanism. The plasma FXI activity and FXI antigen of the proband and the family members were detected by clotting assay and ELISA, respectively. The F11 gene was amplified by PCR and sequenced directly. Online bioinformatics software were needed to analyse the mutations. The proband showed a prolonged activated partial thromboplastin time (93.3 s), whose FXI activity and FXI antigen were low to 2, 4.5%, respectively. A novel mutation c.233T>C (p.Leu60Pro) in exon 4 and a previously described mutation c.1253G>T (Gly400Val) were found in the proband. Protein Leu60 is conserved highly among homologous species. Bioinformatics software indicated that Leu60Pro mutation might affect the protein function. Other coagulation abnormalities were not found. We preliminarily considered the mutations Leu60Pro and Gly400Val were responsible for the decrease FXI level in the family. Leu60Pro mutation in the F11 gene has not been described elsewhere.

Identifiants

pubmed: 33443931
doi: 10.1097/MBC.0000000000001010
pii: 00001721-202109000-00007
doi:

Substances chimiques

Factor XI 9013-55-2

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

401-405

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Références

Gailani D, Smith SB. Structural and functional features of factor XI. J Thromb Haemost 2009; 7:75–78.
Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F, et al. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia 2015; 21:496–501.
Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor or XI-deficient kindreds – a clinical and laboratory study. Thromb Haemost 1995; 73:194–202.
Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, et al. European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10:615–621.
Gueguen P, Galinat H, Blouch MT, Bridey F, Duchemin J, Le Gal G, et al. Biological determinants of bleeding in patients with heterozygous factor XI deficiency. Br J Haematol 2012; 156:245–251.
Asakai R, Davie EW, Chung DW. Organization of the gene for human factor XI. Biochemistry 1987; 26:7221–7228.
Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16:37–41.
Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85:429–432.
Wu WM, Wang HL, Wang XF, Chu HY, Fu QH, Ding QL, et al. Identification of two novel factor XI nonsense mutation Trp228stop and Trp383stop in a Chinese pedigree of congenital factor XI deficiency. Zhonghua Xue Ye Xue Za Zhi 2003; 24:126–128.
Berrer E, Rimoldi V, Usluer S, Aksu S, Pekcelen Y, Caglayan SH, et al. Characterization of the genetic basis of FXI deficiency in two Turkish patients. Haemophilia 2010; 16:564–566.
Liu H, Wang H-F, Tang L, Yang Y, Wang Q-Y, Zeng W, et al. Genetic analysis in factor XI deficient patients from central China: identification of one novel and seven recurrent mutations. Gene 2015; 561:101–106.
Dai L, Rangarajan S, Mitchell M. Three dominant-negative mutaions in factor XI-deficient patients. Haemophilia 2011; 17:e919–e922.
Kravtsov DV, Wu W, Meijers JCM, Sun MF, Blinder MA, Dang TP, et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood 2004; 104:128–134.

Auteurs

Haixiao Xie (H)

Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou.

Meina Liu (M)

Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou.

Anqing Zou (A)

Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou.

Yaosheng Xie (Y)

Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou.

Jiajia Ye (J)

HwaMei Hospital.
Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH